Lilly Zyprex Phase III results show 3-point advantage in schizophrenia symptom score v. haloperidol .
Executive Summary
LILLY ZYPREX SHOWS THREE-POINT ADVANTAGE IN SCHIZOPHRENIA SYMPTOM SCORE over haloperidol treatment based on six-week data in a Phase III study presented Dec. 15 at the American College of Neuropsychopharmacology meeting in San Juan, P.R. Patients receiving Lilly's antipsychotic Zyprex (olanzapine) showed an average decrease of 10.9 points on the Brief Psychiatric Rating Scale compared to an average decrease of 7.9 points for haloperidol-treated patients, Lilly said.